Posted by Michael Wonder on 04 Sep 2019
Forty Seven granted fast track designation for magrolimab for the treatment of myelodysplastic syndrome and acute myeloid leukaemia
3 September 2019 - Forty Seven today announced that the U.S. FDA has granted fast track designation to magrolimab (formerly known as 5F9) for the treatment of myelodysplastic syndrome and acute myeloid leukaemia.
Magrolimab is a monoclonal antibody against CD47 that is designed to block the “don’t eat me” signal used by cancer cells to avoid being ingested by macrophages.
Magrolimab is a monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPα receptor on macrophages, thus blocking the "don't eat me" signal used by cancer cells to avoid being ingested by macrophages.
